TOGETHER-PsA is a Lilly-sponsored, open-label phase 3b trial in 271 adults with active psoriatic arthritis and overweight or obesity. At week 52, 43.7 percent of people assigned to ixekizumab plus tirzepatide reached ACR50 joint improvement versus 15.7 percent on ixekizumab alone, and 85.7 percent versus 6.7 percent lost at least 10 percent of body weight. The week 52 analyses were exploratory, and the design cannot separate weight loss from any direct effect on joint inflammation.
Ask PeptideBlog about any peptide
Research snapshot
| Category | Current information |
|---|---|
| Compounds | Ixekizumab (Taltz), an IL-17A antibody and not a peptide, plus tirzepatide (Zepbound), a dual GIP and GLP-1 receptor agonist (see the tirzepatide entry) |
| Primary research interest | Whether adding weight-loss treatment to a biologic improves psoriatic arthritis control in people with obesity or overweight |
| Highest available evidence | Published randomized human trial (Tier 1), open-label, sponsor-run |
| Human research available | Yes: one randomized trial (271 analyzed), with two smaller studies still running |
| Development status | Phase 3b TOGETHER-PsA completed; phase 4 single-arm AMPLIFY-PsA active, not recruiting; mechanism study COMBAT-PsA recruiting |
| Regulatory status | Each drug is approved on its own. The sources read describe no regulatory filing for the pair as a regimen |
What the trial tested
TOGETHER-PsA randomized adults with active psoriatic arthritis (PsA) and overweight or obesity to ixekizumab alone or ixekizumab plus tirzepatide. Ixekizumab blocks interleukin-17A, an inflammation signal, and is approved for PsA. Tirzepatide is approved for weight management in obesity, or in overweight with a weight-related condition. Eli Lilly makes both drugs and sponsored the trial. For the drug itself, see the tirzepatide entry and the tirzepatide dosage page.
Everyone knew which treatment they were getting. Blinded assessors did the joint counts, enthesitis, dactylitis and skin scores, but patients, sites and the sponsor knew the assignment. The authors chose this design because people on tirzepatide would probably work out their group from early weight loss anyway. Both groups received individual diet and exercise counseling. There was no placebo injection and no tirzepatide-only group.
Week 36 and week 52 results side by side
ACR50 means at least a 50 percent improvement on the American College of Rheumatology joint response scale. It requires a 50 percent drop in both tender and swollen joint counts plus 50 percent improvement in three of five other measures: pain, patient global assessment, physician global assessment, a disability questionnaire and C-reactive protein.
| Measure | Week 36: ixekizumab alone | Week 36: plus tirzepatide | Week 52: ixekizumab alone | Week 52: plus tirzepatide |
|---|---|---|---|---|
| ACR50 and 10 percent or more weight loss (percent) | 0.8 | 31.7 | 1.7 | 39.2 |
| ACR50 (percent) | 20.4 | 33.5 | 15.7 | 43.7 |
| ACR20 (percent) | 48.5 | 71.3 | 35.8 | 73.3 |
| 10 percent or more weight loss (percent) | 4.5 | 84.5 | 6.7 | 85.7 |
| Body weight change (percent) | -1.1 | -18.0 | -0.6 | -20.4 |
| Minimal disease activity (percent) | 15.3 | 26.3 | 13.6 | 28.2 |
| DAPSA change from baseline | -23.7 | -32.4 | -20.3 | -32.2 |
| hsCRP change (mg/L) | -0.44 | -1.79 | -0.4 | -2.2 |
| HAQ-DI change | -0.3 | -0.5 | -0.3 | -0.6 |
| FACIT-Fatigue change (points) | 4.8 | 8.6 | 4.8 | 9.7 |
Week 36 was the planned primary time point. The primary composite and the key secondary measures, including ACR50 on its own, were controlled for multiple testing there. The paper labels every week 52 result exploratory, with nominal P values. All figures use a hypothetical estimand with multiple imputation, explained below. For DAPSA (a joint and skin disease activity score), hsCRP and HAQ-DI, a larger negative number means more improvement. For FACIT-Fatigue, a larger positive number means less fatigue. The 52-week paper is titled “Durable and Additive Disease Control,” and Lilly’s release headline also says durable, while the estimates behind that word are exploratory.
Evidence label: published human clinical trial (Tier 1), open-label, sponsor-run. Sources: the 36-week paper (DOI) and the 52-week paper (DOI).
What was given: doses and schedule
Ixekizumab was given as 160 mg under the skin at week 0, then 80 mg every four weeks (the psoriasis-approved schedule for the few participants with moderate-to-severe psoriasis). Tirzepatide was given once weekly under the skin, starting at 2.5 mg for four weeks and rising in 2.5 mg steps every four weeks to each person’s maximum tolerated dose (5, 10 or 15 mg). From week 32 onward, the permitted maintenance dose was 5, 10 or 15 mg.
Among combination-arm participants with dosing data, the final dose at week 52 was 15 mg for 65.2 percent, 10 mg for 10.9 percent and 5 mg for 13.0 percent. At week 36 the split was 78.9, 8.3 and 9.2 percent. The listed shares do not sum to 100 percent, and the text reviewed does not say what the rest took. This documents what the trial used. It is not a recommendation for any reader. Evidence label: published human clinical trial.
How much of the headline is weight loss
The planned primary endpoint asked for two things at once: ACR50 and at least 10 percent weight loss. At week 36, 31.7 percent of the combination group met it against 0.8 percent on ixekizumab alone. Because 84.5 percent of the combination group lost at least 10 percent of body weight against 4.5 percent of the comparison group, the composite mostly tracks weight. On these numbers it would favor the combination group even if ACR50 alone were identical in both groups. That is this page’s arithmetic, not a statement from the paper.
The joint signal sits in ACR50 on its own: 33.5 percent versus 20.4 percent at week 36, a 13.1 point difference with a 95 percent confidence interval of 2.1 to 24.1 (P = 0.02). That difference was multiplicity-controlled, and the interval is wide, with its low end near zero.
Why the gap widened between week 36 and week 52
The ACR50 gap grew from 13.1 points at week 36 to 28.0 points at week 52 (95 percent confidence interval 17.1 to 38.9). Of the 14.9 point widening, 10.2 points came from the combination group rising (33.5 to 43.7 percent) and 4.7 points from the ixekizumab-alone group falling (20.4 to 15.7 percent). On DAPSA the combination group was flat while the comparison group drifted back toward baseline.
| Measure | Ixekizumab alone, week 36 to week 52 | Plus tirzepatide, week 36 to week 52 |
|---|---|---|
| ACR50 (percent) | 20.4 to 15.7 | 33.5 to 43.7 |
| ACR20 (percent) | 48.5 to 35.8 | 71.3 to 73.3 |
| Minimal disease activity (percent) | 15.3 to 13.6 | 26.3 to 28.2 |
| DAPSA change from baseline | -23.7 to -20.3 | -32.4 to -32.2 |
| Pain score change (mm, 0 to 100 scale) | -21.9 to -14.4 | -25.3 to -25.8 |
The authors attribute the comparison group’s decline to “some general loss of effect with monotherapy,” describe the ACR50 drop as small with overlapping confidence intervals, and cite a similar pattern in an earlier ixekizumab trial (not checked for this page). They read the larger pain-score gap at week 52 as further improvement with the combination. The table shows that gap opened mainly because the comparison group slipped while the combination group stayed about where it was. These comparisons put two separate analyses side by side and are this page’s arithmetic.
Two facts limit how far this can be pushed either way. By week 52, 36.8 percent of the ixekizumab-alone group had stopped treatment, against 20.3 percent of the combination group. Under the trial’s estimand, data after stopping the assigned drug or starting a prohibited medicine are removed and replaced by multiple imputation, run separately in each arm. So the week 52 figure for ixekizumab alone rests partly on imputed values, and the text of the 52-week paper does not describe a sensitivity analysis testing how much that matters.
The two papers also read differently on rescue treatment. The 36-week paper says investigators could adjust background therapy after week 36 if joint counts had not improved by 20 percent. The 52-week paper says additional biologic therapy or changes in therapy were not permitted to week 52. Neither reports how many people in each arm triggered that rule.
Weight loss or something else
Neither paper contains a mediation analysis, the kind of statistical test that estimates how much of a drug effect travels through weight loss. What the authors point to instead is timing. ACR50 differed between groups as early as week 4 (nominal P below 0.05), and hsCRP, a blood marker of inflammation, was numerically lower in the combination group before large weight loss had occurred. The 36-week paper says this suggests a weight-independent benefit. The 52-week paper reads the further hsCRP fall as a possible anti-inflammatory effect of tirzepatide. Both papers say more studies are needed.
That timing argument has gaps. The week 4 comparison is nominal and not controlled for multiple testing. ACR50 includes three patient-reported items (pain, patient global assessment and the disability questionnaire) in a trial where patients knew their treatment, and the authors acknowledge that expectation bias may have influenced patient-reported outcomes. The paper’s own introduction notes that weight reduction has itself been linked to better PsA outcomes. And with no tirzepatide-only group, the trial cannot say what tirzepatide does for PsA by itself.
The blinded measures also favor the combination. At week 52, tender joint count fell by 16.2 versus 11.2 and swollen joint count by 9.7 versus 5.9 (nominal P below 0.001 for both). Those counts came from blinded assessors, which makes them the strongest evidence in the paper that the joint difference is more than expectation. They still cannot show whether weight loss or something else produced it.
Who was studied
A total of 405 people were screened. The 52-week paper’s flow figure says 279 were randomized and 271 analyzed; eight were excluded for lacking a qualifying weight-related condition after an early change in eligibility rules, although both abstracts say 271 were randomized. Average BMI was 37.6, 87.5 percent had a BMI of 30 or higher, 69.7 percent were women and 84.1 percent were White (3.3 percent Black or African American). Sites were in the United States and Puerto Rico.
About 63 percent had used a biologic or targeted synthetic DMARD before, and 18.8 percent had failed two or more classes. Psoriasis was not required: average baseline PASI was 3.3 and only 4.4 percent had moderate-to-severe plaque psoriasis, so the skin results rest on a subset of 151 people with at least 3 percent body surface involvement. People with prior failure or intolerance of an IL-17 inhibitor or a GLP-1 drug were excluded, as was anyone who had used ixekizumab or tirzepatide. At baseline the ixekizumab-alone group had a higher mean DAPSA (55.4) than the combination group (47.2), so the groups were not perfectly balanced.
Side effects and safety signals
Safety data cover the treatment period plus four weeks of follow-up in 270 people (138 combination, 132 ixekizumab alone). Gastrointestinal events were more common with tirzepatide: nausea 29.7 versus 3.0 percent, diarrhea 18.8 versus 5.3, constipation 16.7 versus 3.0 and vomiting 10.9 versus 0.8. Injection site reactions were similar (15.9 versus 16.7 percent). Serious adverse events occurred in 4.3 percent (6 people) of the combination group and 8.3 percent (11 people) of the ixekizumab-alone group. Stopping treatment for any adverse event was similar (6.5 versus 5.3 percent), while stopping for gastrointestinal events was 3.6 versus 0.8 percent. No deaths were reported. ALT, a liver enzyme, fell 22.7 percent in the combination group and rose 5.6 percent with ixekizumab alone (post hoc).
The week 52 safety table also lists events that were new since week 36, all in the combination group: one case of pancreatitis that was severe, required hospitalization and was judged related to study treatment; pancreatic adenocarcinoma in the same participant, judged not related; one stage 0 malignant melanoma, also judged not related; and an intestinal obstruction. The authors conclude there were no new safety concerns, and the Discussion text does not address these events. One case in 138 people cannot establish a rate, and a 52-week trial of this size cannot detect rare events. The trial excluded anyone with a history of pancreatitis.
Who paid for it and who wrote it
Eli Lilly supported the trial and, according to the paper, contributed to its design, data collection, analysis, interpretation, manuscript preparation and the decision to submit. Eight of the 15 authors list a Lilly affiliation, and medical writing support came from a Lilly employee. Lilly makes both drugs. The paper states that publication was not contingent on Lilly’s approval and that all authors had full access to the data. Individual disclosures for the outside authors are in a separate form on the journal page. Lilly says anonymized participant-level data can be requested through Vivli six months after the indication studied is approved in the United States and the European Union.
What comes next
Three registered studies bear on the open questions.
- AMPLIFY-PsA (NCT06864026): a phase 4, open-label, single-arm study that adds tirzepatide in people about three months into ixekizumab treatment, with 200 planned participants. The registry lists it as active, not recruiting, with primary completion in August 2027. Primary outcomes are a HAQ-DI of 0.5 or lower and at least 10 percent weight loss at 12 months. With no comparison group it can describe outcomes but cannot show that tirzepatide caused them. A narrative review published in April 2026 groups it with TOGETHER-PsA as a trial of ixekizumab with and without tirzepatide, while the registry entry describes a single group.
- COMBAT-PsA (NCT07443956): a small mechanism study run from NHS Greater Glasgow and Clyde, with the University of Glasgow and Lilly as collaborators, planning 45 participants in three groups (tirzepatide alone, ixekizumab alone, both) with joint, skin and fat biopsies. The registry lists it as recruiting, with primary completion in February 2028, and calls it experimental medicine rather than an efficacy study. It is the study in this set with a tirzepatide-alone group, which is what the weight-versus-direct-effect question needs.
- TOGETHER-PsO: the authors cite 36-week results from this trial in moderate-to-severe psoriasis. Those results were not reviewed for this page.
What the trial does not show
- It does not show a placebo-controlled effect, because the comparison group received ixekizumab alone with no placebo injection.
- It does not separate tirzepatide’s weight effect from any direct effect on joints, because it had no tirzepatide-only group and reports no mediation analysis.
- It does not compare the combination with other advanced therapies, so it cannot say how ixekizumab plus tirzepatide ranks against a more effective biologic alone.
- It does not confirm the week 52 results, which the paper labels exploratory, and it reports no joint-damage imaging outcome and no data past 52 weeks.
- It does not cover people with a BMI below 27, people who failed an IL-17 inhibitor, or care settings outside the United States and Puerto Rico.
Regulatory and development status
According to the 52-week paper, ixekizumab is FDA-approved for psoriatic arthritis and tirzepatide is approved for obesity, or for overweight with at least one weight-related condition. Each approval covers the single drug. The trial gave both at US-approved doses, and the sources read for this page describe no regulatory submission for the combination as a regimen. TOGETHER-PsA is registered as completed, with a registry completion date of April 23, 2026. Status is as of the November 11, 2026 publication of the 52-week paper.
Frequently asked questions
What is TOGETHER-PsA?
A Lilly-sponsored, randomized, open-label phase 3b trial (NCT06588296) in 271 adults with active psoriatic arthritis and overweight or obesity. It compared ixekizumab alone with ixekizumab plus tirzepatide, with blinded assessors for joint and skin scores.
What did TOGETHER-PsA find at 52 weeks?
ACR50 was 43.7 percent with ixekizumab plus tirzepatide versus 15.7 percent with ixekizumab alone. At least 10 percent weight loss was reached by 85.7 versus 6.7 percent, and mean body weight change was -20.4 versus -0.6 percent.
Were the week 52 results confirmatory?
No. The primary endpoint was assessed at week 36. The paper labels the week 52 analyses prespecified but exploratory, with no multiplicity control and nominal P values.
Does the trial show tirzepatide helps psoriatic arthritis independent of weight loss?
No. Neither paper includes a mediation analysis, and the trial had no tirzepatide-only group. The authors point to early ACR50 and hsCRP differences as suggestive and say more studies are needed.
What tirzepatide dose did the trial use?
Weekly injections starting at 2.5 mg and rising by 2.5 mg every four weeks to each person’s maximum tolerated dose (5, 10 or 15 mg). From week 32 onward, 5, 10 or 15 mg was the permitted maintenance dose. At week 52, 65.2 percent of those with dosing data were on 15 mg. This documents the trial, not a recommendation.
Why did ACR50 fall in the ixekizumab-alone group between weeks 36 and 52?
The paper does not test the reason. The authors call the drop small with overlapping intervals and attribute it to some loss of effect with monotherapy. About 37 percent of that group had stopped treatment by week 52, and their data were imputed.
What side effects were reported?
Nausea, diarrhea, constipation and vomiting were more common with the combination. Serious adverse events were 4.3 versus 8.3 percent. The week 52 table also lists one pancreatitis case judged related to treatment, in the combination group.
Who funded TOGETHER-PsA?
Eli Lilly, which makes both drugs. Lilly contributed to design, data analysis, interpretation, manuscript preparation and the decision to submit, and eight of 15 authors list Lilly affiliations.
Bottom line
TOGETHER-PsA is the first randomized trial of ixekizumab with tirzepatide in psoriatic arthritis with obesity. Its weight result is objective and large: mean body weight fell 20.4 percent at week 52 against 0.6 percent. At the planned week 36 analysis the combination beat ixekizumab alone on ACR50 by 13.1 points (95 percent confidence interval 2.1 to 24.1), and blinded joint counts pointed the same way at week 52.
The 28.0 point ACR50 gap at week 52 is exploratory, and roughly a third of its widening came from the comparison group slipping, in an arm where 36.8 percent had stopped treatment. The trial was open-label and run by the maker of both drugs. It cannot say whether weight loss, a direct drug effect or expectation drove the joint results, and it has no tirzepatide-only group or mediation analysis to try. COMBAT-PsA, a small three-group mechanism study, is the registered study built to address that. Educational reference only: this page documents what a published trial reported and does not tell any reader what to take.
Sources
- Merola JF, Kartman CE, Fischer P, et al. Durable and additive disease control at 52 weeks with ixekizumab plus tirzepatide versus ixekizumab alone in adults with psoriatic arthritis and obesity or overweight. Arthritis & Rheumatology. Published online November 11, 2026. https://doi.org/10.1002/art.70375 (PubMed 43012507). Evidence category: published randomized human trial, open-label, sponsor-run (Tier 1).
- Merola JF, Mease P, Kivitz A, et al. Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity. Arthritis & Rheumatology. 2026;78(10):2089-2101. https://doi.org/10.1002/art.70134 (PubMed 41903163). Evidence category: published randomized human trial, open-label, sponsor-run (Tier 1).
- Eli Lilly and Company. New Phase 3b data on Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity. Press release, November 11, 2026. investor.lilly.com. Evidence category: company press release, not peer reviewed.
- ClinicalTrials.gov. NCT06588296, TOGETHER-PsA. clinicaltrials.gov/study/NCT06588296. Evidence category: government trial registry.
- ClinicalTrials.gov. NCT06864026, TOGETHER AMPLIFY-PsA. clinicaltrials.gov/study/NCT06864026. Evidence category: government trial registry.
- ClinicalTrials.gov. NCT07443956, COMBAT-PsA. clinicaltrials.gov/study/NCT07443956. Evidence category: government trial registry.
- Ciancio G, Maranini B, Sandri G, et al. Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities. Frontiers in Immunology. 2026;17:1744308. https://doi.org/10.3389/fimmu.2026.1744308 (PubMed 42131335). Evidence category: narrative review.
Related reading on this site: the CAMEO-SEMA analysis shows how this site reads a single-center randomized trial, and the tirzepatide dosage page covers the drug in this pairing. On The Weight Loss Atlas: the tirzepatide guide on The Weight Loss Atlas and the Lilly pipeline tracker on The Weight Loss Atlas.